ÌÇÐÄÆƽâ°æ

According to the annual ranking of Forbes Global 2000 which measures the world's largest public companies, Shanghai Pharmaceuticals ranked first among the top Chinese pharmaceutical companies in terms of sales value in 2025, amounting to approximately 38 billion U.S. dollars. China Resources Pharmaceutical Group took the second place with 35.8 billion U.S. dollars in sales value. The third place belonged to Yunnan Baiyao Group with a sales revenue of 5.53 billion U.S. dollars. 

Staying ahead of the game

China’s healthcare market is highly competitive, with over 4,000 pharmaceutical players. Industry giants like Sinopharm and Shanghai Pharmaceuticals usually have strong control over distributor networks, which are essential for reducing costs and achieving faster growth. These market leaders have been eager to progress from an imitator to an innovator, spending hundreds of millions of yuan on developing new drugs and technology. In the eight-year span between 2015 and 2022, Shanghai Pharmaceuticals increased its research and development (R&D) costs from 618 million yuan to more than 2.8 billion yuan. In some firms, the share of sales revenue spent on R&D could reach as high as 12 percent.

A highly competitive market

When it comes to financial health in the pharmaceuticals industry, leading in sales revenue does not always mean yielding the highest profit. In terms of annual profit, the partly state-owned Sinopharm Group stood first again in the Forbes ranking in 2023. However, Jiangsu Hengrui Medicine and Yunnan Baiyao Group overtook Shanghai Pharmaceuticals, and Jointown Pharmaceutical Group was down to the eighth spot. Given the long period of time between initial research and finally launching a product to the health market, it is always challenging for pharmaceutical companies to earn a profitable return on investment.